Home | Welcome to Contract Pharma   
Last Updated Sunday, May 19 2013
Print

Financial Report: Parexel 3Q



By Gil Roth



Published May 1, 2012
Parexel 3Q

3Q Revenues*:
$356 million (+18%)

3Q Earnings: $22.9 million (+46%)

YTD Revenues*: $1.0 billion (+11%)

YTD Earnings: $45.3 million (-10%)

* Consolidated service revenues only

Comments: Backlog at the end of the quarter was approximately $4.2 billion (+33% year-over-year). Reported backlog included gross new business wins of $1.1 billion, cancellations of $263.3 million, and a positive impact from foreign exchange rates, and other small adjustments of $44.3 million. The net book-to-bill ratio was 2.23 in the quarter. Revenues for the quarter were $263.4 million in Clinical Research Services (CRS), $43.3 million in Parexel Consulting and Medical Communications Services (PCMS), and $49.3 million in Perceptive Informatics. New business gains have led to increased hiring and other expenditures, reducing operating margins.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On